Thrombin generation and activated protein C resistance in the absence of factor V leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years

Thrombosis and Haemostasis

Volumn 106, Issue 5, 2011, Pages 901-907

  Sonnevi, Kristina ^a   Tchaikovski, Svetlana N ^b,e   Holmström, Margareta ^c   Rosing, Jan ^b   Bremme, Katarina ^d   Lärfars, Gerd ^a  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

APC resistance; Recurrence; Thrombin generation; Venous thrombosis; Women

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; THROMBOPLASTIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; THROMBIN TIME; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTICOAGULANTS; BLOOD COAGULATION TESTS; DISEASE-FREE SURVIVAL; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SWEDEN; THROMBIN; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 80155184581     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-04-0254     Document Type: Article

References (31)

1. Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg 2003; 25: 1-5.
2. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117: 19-25.
3. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
4. Kyrle PA, Minar E, Bialonczyk C, et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350: 2558-2563.
5. Christiansen SC, Lijfering WM, Helmerhorst FM, et al. Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event. J Thromb Haemost 2010; 8: 2159-2168.
6. Le Gal G, Kovacs MJ, Carrier M, et al. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study. Thromb Haemost 2010; 104: 498-503.
7. Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-2040.
8. Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res 2010; 126: 5-11.
9. Pesavento R, Villalta S, Prandoni P. The postthrombotic syndrome. Intern Emerg Med 2009; 5: 185-192.
10. Douketis JD, Gu CS, Schulman S, et al. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 2007; 147: 766-774.
11. Dargaud Y, Trzeciak MC, Bordet JC, et al. Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost 2006; 96: 562-567.
12. Hron G, Kollars M, Binder BR, et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. J Am Med Assoc 2006; 296: 397-402.
13. Tripodi A, Legnani C, Chantarangkul V, et al. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 2008; 6: 1327-1333.
14. Bergrem A, Dahm AE, Jacobsen AF, et al. Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism. Br J Haematol 2011; 12:1365-2141.
15. Tournier A, Wahl D, Chaouat A, et al. Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension. Thromb Res 2010; 126: e418-422.
16. Tchaikovski SN, van Vliet HA, Thomassen MC, et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost 2007; 98: 1350-1356.
17. Tans G, Vlieg Av H, Thomassen M, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122: 465-470.
18. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983.
19. Wieloch M, Sjalander A, Frykman V, et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 2011; 5: 26.
20. Curvers J, Thomassen MC, Nicolaes GA, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 1999; 1: 88-94.
21. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
22. Holmberg K, Persson ML, Uhlen M, et al. Pyrosequencing analysis of thrombosisassociated risk markers. Clin Chem 2005; 51: 1549-1552.
23. Castoldi E, Rosing J. APC resistance: biological basis and acquired influences. J Thromb Haemost 2010; 8: 445-453.
24. Maurissen LF, Castoldi E, Simioni P, et al. Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals. J Thromb Haemost 2010; 8: 750-758.
25. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-1276.
26. Tripodi A, Legnani C, Lemma L, et al. Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. J Thromb Thrombolysis 2010; 30: 215-219.
27. Dielis AW, Castoldi E, Spronk HM, et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 6: 125-131.
28. de Visser MC, van Hylckama Vlieg A, Tans G, et al. Determinants of the APTTand ETP-based APC sensitivity tests. J Thromb Haemost 2005; 3: 1488-1494.
29. Liestol S, Sandset PM, Mowinckel MC, et al. Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. J Thromb Haemost 2007; 5: 2204-2210.
30. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-1789.
31. Douketis J, Tosetto A, Marcucci M, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to asess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med 2010; 153: 523-531.